have-insiders-been-buying-kala-pharmaceuticals,-inc.-(nasdaq:kala)-shares?

Have Insiders Been Buying Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares?

View photos

NASDAQ:KALA).” data-reactid=”28″ type=”text”>We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So shareholders might well want to know whether insiders have been buying or selling shares in Kala Pharmaceuticals, Inc. (NASDAQ:KALA).

Do Insider Transactions Matter?

It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trading activities, and not trade on inside information.

We don’t think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise’.

View our latest analysis for Kala Pharmaceuticals ” data-reactid=”36″ type=”text”> View our latest analysis for Kala Pharmaceuticals

Kala Pharmaceuticals Insider Transactions Over The Last Year

The Chief Operating Officer Todd Bazemore made the biggest insider purchase in the last 12 months. That single transaction was for US$58k worth of shares at a price of US$5.75 each. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$9.09. Because the shares were purchased at a lower price, this particular buy doesn’t tell us much about how insiders feel about the current share price.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume

list of growing companies that insiders are buying.” data-reactid=”52″ type=”text”>There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Kala Pharmaceuticals insiders own 1.5% of the company, worth about US$7.6m. We do generally prefer see higher levels of insider ownership.

So What Do The Kala Pharmaceuticals Insider Transactions Indicate?

3 warning signs for Kala Pharmaceuticals (of which 1 is a bit concerning!) you should know about.” data-reactid=”56″ type=”text”>There haven’t been any insider transactions in the last three months — that doesn’t mean much. On a brighter note, the transactions over the last year are encouraging. We’d like to see bigger individual holdings. However, we don’t see anything to make us think Kala Pharmaceuticals insiders are doubting the company. In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing Kala Pharmaceuticals. Every company has risks, and we’ve spotted 3 warning signs for Kala Pharmaceuticals (of which 1 is a bit concerning!) you should know about.

list of interesting companies, that have HIGH return on equity and low debt.” data-reactid=”57″ type=”text”>If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”63″ type=”text”>

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top